News
ALLO
2.280
+0.44%
0.010
Allogene Therapeutics schedules first-quarter results, business update webcast and call
PUBT · 3d ago
ALLOGENE THERAPEUTICS TO REPORT FIRST QUARTER FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE
Reuters · 3d ago
Weekly Report: what happened at ALLO last week (0427-0501)?
Weekly Report · 5d ago
Weekly Report: what happened at ALLO last week (0420-0424)?
Weekly Report · 04/27 09:48
Legend Biotech: Undervalued Leader In The CAR-T Race
Seeking Alpha · 04/24 14:04
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO)
TipRanks · 04/22 11:20
Allogene Therapeutics expands Phase 2 ALPHA3 trial to South Korea, Australia
TipRanks · 04/21 12:50
Allogene wins South Korea, Australia regulatory clearance to expand ALPHA3 trial
PUBT · 04/21 12:33
Allogene Therapeutics Receive South Korea, Australia Clearance To Expand Its Pivotal Phase 2 ALPHA3 Trial Of Cemacabtagene Ansegedleucel To Treat Patients With Large B-Cell Lymphoma
Benzinga · 04/21 12:31
ALLOGENE THERAPEUTICS INC - INTERIM EFS ANALYSIS ANTICIPATED IN MID-2027, PRIMARY EFS ANALYSIS IN MID-2028
Reuters · 04/21 12:30
Allogene Therapeutics announces annual shareholder meeting notice
PUBT · 04/20 21:22
Allogene Therapeutics to present allogeneic CAR-T data at AACR annual meeting
PUBT · 04/20 12:36
Allogene presents preclinical BCMA/CD70 dual CAR-T data for multiple myeloma at AACR
PUBT · 04/20 12:31
Weekly Report: what happened at ALLO last week (0413-0417)?
Weekly Report · 04/20 09:46
Allogene Therapeutics closes USD 200.4 million follow-on stock offering at USD 2 per share
PUBT · 04/16 20:02
ALLOGENE THERAPEUTICS ANNOUNCES CLOSING OF $200.4 MILLION PUBLIC OFFERING OF COMMON STOCK
Reuters · 04/16 20:01
Press Release: Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
Dow Jones · 04/16 20:01
Allogene Therapeutics Raised to Neutral From Underweight by JP Morgan
Dow Jones · 04/16 15:14
JP Morgan Upgrades Allogene Therapeutics to Neutral
Benzinga · 04/16 15:05
Aehr Test Systems, CareDx, Okta And Other Big Stocks Moving Higher On Thursday
Benzinga · 04/16 13:56
More
Webull provides a variety of real-time ALLO stock news. You can receive the latest news about Allogene Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.